

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[← Back](#)

[Technologies Available for Licensing](#)

[Patient Support & Treatment](#)

[Refer a Patient](#)

## ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

nuclear localized factors by conventional means had previously proven problematic. Using a modified antisense conjugated to an endothelium-specific homing peptide, the researchers demonstrated usefulness of the Id-1 PCAO compound as both a single agent and in combination therapy in preclinical models of primary tumor growth and metastasis. Further, this technology circumvents challenges associated with traditional antisense therapeutics by efficiently reaching local targets by systemic delivery, by facilitating cellular uptake, and by prolonging the stability of the compound.

## Advantages

- Minimal side effects predicted: No effect on wound healing or weight, no gross histological signs of toxicity observed.
- Successful in both xenografts and spontaneous breast tumor models, as single agent and in combination therapy.
- Prolonged plasma stability of peptide-linked antisense oligonucleotides shown.
- Preferential delivery to tumor site and compartmentalization of compound established.
- Mechanism of uptake of compound elucidated.

## Areas of Application

- Id-1 PCAO compound for reduction of primary tumor size and prolonged life following metastasis by targeting endothelium of tumors.
- Other cancer types and antisense are being tested.
- Technology may be a universally applicable tool for antisense delivery in cancer and other diseases.

## Stage of Development

The researchers motivated and ready to initiate clinical development. We are looking to identify the best way to develop both the compound Id-1 PCAO and the technology in a broader context. This may be an ideal platform for an already existing company or serve as the basis for formation of a new company.

## Lead Inventor

[Robert Benezra](#), PhD, Laboratory Head, Cancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering

## Patent Information

US Continuation in part and Divisional patents issued.

## References

Henke E, et al. [\(2008\) Nature Biotechnology 26: 91-100](#)

## Contact Information

Lisa Kennedy, PhD, Senior Manager, Business Development & Licensing

Email: [kennedl1@mskcc.org](mailto:kennedl1@mskcc.org)

## Stage of Development

Ready to use

## Indications

[Indications](#) › [Cancer](#)

## Types

[Therapeutics](#) › [Nucleic acids](#)

### Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



### About MSK

[About us](#)

[Careers](#) 

[Giving](#) 

## ▾ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

## ▾ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) 

[Graduate medical education](#)

[MSK Library](#) 

---

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center